Metoclopramida Labesfal

Metoclopramide, the active ingredient in Metoclopramida Labesfal, is a dopamine D2 receptor antagonist presented as an oral dosage form for oral use. It is employed to treat nausea, vomiting, gastroparesis and related gastrointestinal motility disorders in adult patients.

GNH USA supplies Metoclopramida Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic and serotonergic pathways to control emesis and improve gastrointestinal motility. - Nausea and vomiting: reduces the frequency and severity of acute and chemotherapy‑induced episodes. - Gastroparesis: enhances gastric emptying and alleviates associated symptoms. - Gastroesophageal reflux disease: improves lower esophageal sphincter tone and reduces reflux episodes.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: transient sleepiness or fatigue. - Restlessness: feelings of inner tension or akathisia. - Diarrhea: loose stools or increased bowel movements. - Headache: mild to moderate cranial pain.

Serious or Rare Side Effects: - Extrapyramidal reactions: muscle rigidity, tremor, or dystonia. - Tardive dyskinesia: persistent involuntary movements after prolonged use. - Neuroleptic malignant syndrome: life‑threatening hyperthermia and muscle breakdown.

Metoclopramide requires careful use in several clinical situations. - Contraindicated in patients with bowel obstruction: risk of perforation. - Caution in renal impairment: reduced clearance may increase toxicity. - Monitor for extrapyramidal symptoms: early detection prevents progression. - Avoid in known hypersensitivity to metoclopramide or its excipients. - Use with caution in the elderly: heightened central nervous system effects. - Store at room temperature: keep in the original pack, protect from moisture.

Metoclopramide can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive dopamine blockade may increase extrapyramidal risk. - MAO inhibitors: combined serotonergic activity can precipitate serotonin syndrome. - CNS depressants (e.g., benzodiazepines): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Opioids: may augment gastrointestinal side effects. - Antihistamines: increased drowsiness. - SSRIs and SNRIs: potential for additive serotonergic effects. - Anticholinergics: may reduce pro‑kinetic benefit.